We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Lipocalin 2 Proposed as Biomarker for Bacterial Meningitis

By LabMedica International staff writers
Posted on 05 Aug 2020
Print article
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Central nervous system (CNS) infections cause significant mortality and morbidity worldwide. Common CNS infections include bacterial meningitis (BM) other than tuberculosis, viral encephalitis, tuberculous meningitis (TBM) and cryptococcal meningitis, but there are more than 100 documented infectious causes of CNS infections.

Clinical features are often insufficient to discriminate the likely cause and standard laboratory investigations identify the causative agent in less than 60% of cases. Critically, the clinical management of CNS infections varies according to its etiology. Therefore, rapid and accurate identification of the likely cause of the infection is essential to initiate appropriate therapy and improve patient outcome.

Scientists from the Oxford University Clinical Research Unit (Ho Chi Minh City, Vietnam) and their associates applied liquid chromatography tandem mass-spectrometry on 45 cerebrospinal fluid (CSF) samples from a cohort of adults with/without CNS infections to discover potential diagnostic biomarkers. They then validated the diagnostic performance of a selected biomarker candidate in an independent cohort of 364 consecutively treated adults with CNS infections admitted to a referral hospital in Vietnam.
Gold Supplier
Cytopro Cytocentrifuge Series 2
SARS-CoV-2 Antigen Test
2019-nCoV Antigen Test (Lateral Flow Method)
Visit expo >

Measurement of lipocalin 2 (LCN2) concentrations was performed on CSF samples and a subset of plasma samples of the study participants using monoclonal antibody based Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA) which costs around USD 10/test. CSF was analyzed as individual samples using proteomic platforms. MS/MS spectra were searched against the UniProt Homo Sapiens Reference proteome. Deamidation on asparagine and glutamine and oxidation on methionine were included as variable modifications.

The team identified LCN2 as a potential biomarker of BM other than tuberculous meningitis. The analysis of the validation cohort showed that LCN2 could discriminate BM from other CNS infections (including tuberculous meningitis, cryptococcal meningitis and viral/antibody-mediated encephalitis), with the sensitivity of 0.88, the specificity equaled 0.91 and the diagnostic odds ratio was 73.8. LCN2 outperformed other CSF markers (leukocytes, glucose, protein and lactate) commonly used in routine care worldwide. The combination of LCN2, CSF leukocytes, glucose, protein and lactate resulted in the highest diagnostic performance for BM (area under receiver-operating-characteristic-curve = 0.96).

The authors concluded that their results suggest that LCN2 is a sensitive and specific biomarker for discriminating BM from a broad spectrum of other CNS infections. A prospective study is needed to assess the diagnostic utility of LCN2 in the diagnosis and management of CNS infections. The study was published on July 10, 2020 in the journal Clinical Microbiology and Infection.

Related Links:
Oxford University Clinical Research Unit
R&D Systems

Print article



view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more


view channel

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.